Article information
Full text is only aviable in PDF
BIBLIOGRAFIA
[1.]
Control Centers For Disease.
Core curriculum on tuberculosis What the clinician should know.
Atlanta Centers for Disease Control, (1994),
[2.]
J.J. Ellner.
Pathogenesis and Immunology.
Tuberculosis Clinical Management and New Chalenges,
[3.]
S.M. Garay.
Pulmonary Tuberculosis.
Tuberculosis,
[4.]
M.J.M. Gomes, J.P. Mata, et al.
Tuberculose aspectos actuais, Deparatmento de Pneumologia Hospital Pulido Valente. Faculdade de Ciências Médicas da Universidade Nova, (1992),
[5.]
J.D.H. Porter, K.P. McAdam.
The re-emergence of tuberculosis.
Annu Rev Public Health., 15 (1994), pp. 303-323
[6.]
M.L. Antunes, A.F. Antunes.
The tuberculosis situation in Portugal a historical perspective to 1994.
Eurosurveillance, 2 (1996), pp. 19-21
[7.]
A. Ramalho.
A tuberculose Doença do passado, do presente e do futuro.
Porto Laboratórioes Bial, (1995),
[8.]
Direcção Geral De Saúde.
Comissão Nacional de Luta Contra a Tuberculose Programa nacional de luta contra a tuberculose.
Editorial Rev Port Pneumol, 2 (1995), pp. 2-6
[9.]
D. Antoine, V. Schwoebel, et al.
Surveillance of tuberculosis in the WHO European region, 1995-1996.
Eurosurveillance, 3 (1998), pp. 103-107
[10.]
A.F. Antunes, A. Lgrça.
A tuberculose notificada.
Saúde em números, 13 (1998), pp. 6-7
[11.]
J.A. Pilheu.
Tuberculosis 2000 problems and solutions.
Int J Tubere. Lung Dis, 2 (1998), pp. 696-703
[12.]
DIRECÇÃO GERAL DE SAÚDE Tuberculose em Portugal 1995, Estaisticas e aspectos epidemiológicos Lisboa: Direcção Geral de Saúde Núcleo de Tuberculose e Doenças Respiratórias.
[13.]
DIRECÇÃO GERAL DE SAÚDE Doenças de declaração obrigatória, 1990/1996. Lisboa: Direcção Geral da Saúde, 1998. Disponível em URL http://www.Dgsaude.pt/html/deb/dtdo.
[14.]
A.P. Mendez, M.C. Raviglione, A. Lazlo, et al.
Global surveillance for antituberculosis-drug resistance.
N Engl J Med, 338 (1998), pp. 1641-1649
[15.]
Who/Iuatld.
global project on anti-tuberculosis drug resistance surveillance Anti-tuberculosis drug resistance in the world, World Health Organization, (1997),
[16.]
M.N. Gourevitch, P. Alcabes, et al.
Cost-effectiveness of directly observed chemoprophylaxis or tuberculosis among drug users at high risk for tuberculosis.
Int J Tuberc Lung Dis, 2 (1998), pp. 531-540
[17.]
S.J. Heymann, R. Sell, et al.
The influence of program acceptability on the effectiveness of public health policy a study of directly observed therapy for tuberculosis.
Am J public Health, 88 (1998), pp. 442-445
[18.]
J. Grosset.
Current problems with tuberculosis treatment.
Res microbol, 147 (1996), pp. 10-16
[20.]
J.H. Grosset.
The history of chemotherapy for tuberculosis.
Int J Tuberc Lung Dis, 2 (1998), pp. 165-166
[21.]
D.A. Mitchison.
How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis.
Int J Tuberc Lung Dis, 2 (1998), pp. 10-11
[22.]
M. Lipsitch, B.R. Levin.
Population dynamics of tuberculosis treatment, mathematical models of the roles of non compliance and bacterial heterogeneity m the evolution or drug resistance.
Int J Tuberc Lung Dis, 2 (1998), pp. 187-199
[23.]
M.C. White, J.P. Tulsky, P. Reilly, et al.
A clinical trial of financial incentive to go to the tuberculosis clinic for isoniazid after release from jail.
Int J tuberc Lung Dis, 2 (1998), pp. 506-512
[24.]
B. Mendes, C. Gomes, et al.
Estudo da prevalência da resistência aos antibacilares.
Rev Port Pneumol, 3 (1996), pp. 375-380
[25.]
T.M. Comolet, R. Rakotomalala, et al.
Factors determining compliance with tuberculosis treatment 111 an urban environment. Tamatave, Madagascar.
Int J Tuberc Lung Dis, 2 (1998), pp. 891-897
[26.]
J. Volmink, P. Garner.
Systematic review of randomised controlled trials of strategies to promote adherence to tuberculosis treatment.
BMJ, 315 (1997), pp. 1403-1406
[27.]
C.L. Fallab-Stubi, J.P. Zellweger.
Electronic monitoring of adherence to treatment in the preventive chemotherapy of tuberculosis.
Int J Tuberc Lung Dis, 2 (1998), pp. 525-530
[28.]
P. Sonnenberg, M.H. Ross, et al.
The effect of dosage cards on compliance with directly observed tuberculosis therapy in hospital.
Int J Tuberc Lung Dis, 2 (1998), pp. 168-171
[29.]
J. Dick, C. Lombard.
Shared vision – a health education project designed to enhamce adherence to anti-tuberculosis treatment.
Int J Tuberc Lung Dis, 1 (1997), pp. 181-186
[30.]
B.T. Mangura, B.T. Passannante, et al.
An incentive in tuberculosis preventive therapy for an inner city population.
Int J Tuberc Lung Dis, 1 (1997), pp. 576-578
[31.]
J.S. Marinac, S.K. Willsie, et al.
Knowledge of tuberculosis in high-risk populations: survey of inner city minorities.
Int J Tuberc Lung Dis, 2 (1998), pp. 804-810
[32.]
W.J. Burman, C.B. Dalton, et al.
A cost-effectiveness analysis of directly observed therapy vs self administered therapy for treatment of tuberculosis.
Chest, 112 (1997), pp. 63-70
[33.]
W.J. Burman, D.L. Conh, et al.
Noncompliance with directly observed therapy for tuberculosis Epidemiology and effect on the outcome of treatment.
Chest, 111 (1997), pp. 1168-1173
[34.]
C.P. Chaulk, V.A. Kazandjian.
Directly observed therapy for treatment completion of pulmonary tuberculosis Consensus Statement of the Public health tuberculosis Guidelines Panel.
JAMA, 279 (1998), pp. 943-948
[35.]
J. Crofton, P. Chaulet, D. Maher.
editors Guidelines for the management of drug-resistant tuberculosis.
World Health Organization, (1997),
[36.]
D. Maher, P. Chaulet, et al.
Tretament guidelines for national programmes.
World Health Organization, (1997),
[37.]
R. Bayer, C. Stayton, et al.
Directly observed therapy and treatment completion for tuberculosis in the United States is universal supervised therapy necessary?.
Am J Public Health, 88 (1998), pp. 1052-1058
[38.]
R. Bayer, L. Dupuis.
Tuberculosis, public health. and civil liberties.
Annu Rev Public Health, 16 (1995), pp. 307-326
Copyright © 1999. Sociedade Portuguesa de Pneumologia/SPP
Special content about COVID-19
- Hyperoxemia in invasively ventilated COVID–19 patients–Insights from the PRoVENT–COVID study
- Association between respiratory distress time and invasive mechanical ventilation in COVID-19 patients: A multicentre regional cohort study
- Assisted mobilisation in critical patients with COVID-19
- Two years of COVID-19: Trends in rehabilitation
Recommended
articles
articles
Pulmonol. 2021;27:469-71
Open access
This work is licensed under a Creative Commons Attribution 4.0 International License.
Publish in
Pulmonology
Pulmonology
- Home
- All contents
- Publish your article
- About the journal
- Metrics
- Open access
Article options